Please login or register to print this page.

Clinical Articles, Lead Article

ATTEST study – impact of early radiofrequency ablation on AF

The Atrial Fibrillation (AF) Progression Trial (ATTEST) has started enrollment, aiming to determine whether superior effectiveness in early radiofrequency ablation (RFA) compared with standard drug therapy, delays progression of Paroxysmal Atrial Fibrillation (PAF).

The primary endpoint of the study will be disease progression at three years, which has been studied less commonly than other long-term outcomes in AF such as AF recurrence. The primary investigator of the study, sponsored by Biosense Webster) is Professor Karl-Heinz Kuck from ASKLEPIOS Klinik St. Georg (Hamburg, Germany).

RFA is recommended as second-line therapy in the current AF management guidelines (ACC/AHA/ESC and ACCF/AHA/HRS) .  However, comparative data on AF progression after catheter ablation versus without ablation are limited.

ATTEST will compare the progression of AF in two randomised treatment groups: pulmonary vein isolation (PVI) and drug therapy. The study will enroll approximately 330 patients at up to 50 sites primarily in Europe and Asia.


Professor Karl-Heinz Kuck

Ablation treatment will be used in the PVI group and the most effective AF medication for either rate or rhythm control will be used in the drug group. The study duration is anticipated to be four to five years including three years of follow-up on all patients.

Secondary endpoints in the ATTEST study include but are not limited to: the effectiveness in AF recurrence prevention, the influence of various co-morbidities in AF disease progression, the safety of treatment options, as well as patient quality of life and health economics.

Published on: March 9, 2012

Members Area

Log in or Register now.

 For healthcare professionals only
Anticoagulation sky



Subscribe to our RSS feed


Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.


    None Found


  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.